New: NCI-funded clinical trial search
Mednet Logo
CommunityHematology

Hematology

Clinical discussions on blood disorders, coagulation, transfusion medicine, and hematologic malignancies.

Recent Discussions

Would you offer live vaccines (e.g., MMRV/measles) to patients on bispecific antibodies for multiple myeloma?

1
2 Answers

Mednet MemberInvited Expert
Medical Oncology · Loyola University Medical Center

I agree with the answer here by Dr. @Dr. First Last. There are a lot of nuances, though. In regard to giving the vaccine safely and effectively, the best strategy is not to wait until patients have multiple relapses and are on bispecific therapy to vaccinate. Given the recent outbreaks of measles, i...

How do you approach initial anticoagulant selection in hemodynamically stable hospitalized patients with newly diagnosed pulmonary embolism?

2
1 Answers

Mednet MemberInvited Expert
Hospital Medicine · University of California, San Diego

Low-molecular-weight heparin demonstrates the greatest benefit in patients with cancer-associated pulmonary embolism, intermediate-risk PE, and those requiring outpatient management. While LMWH shows superior efficacy and safety compared to unfractionated heparin across most patient populations, cer...

What is your preferred assay for assessing dabigatran levels?

1 Answers

Mednet MemberInvited Expert
Hematology · Mayo Clinic

The only specific assay that would reflect drug levels is the ecarin clotting time with dabigatran as a calibrator. We used to have this assay in our lab, but due to a lack of use, it was discontinued. The standard thrombin time is too sensitive; however, dilute thrombin time has been used. The mass...

About Mednet

A community where doctors find answers to medicine's toughest questions.

  • Verified, credentialed physicians
  • 45,000+ members across 24 specialties
  • Free CME and MOC credit

What guides your choice between prophylactic, intermediate, and full therapeutic dosing of enoxaparin in a woman with APLS and prior fetal loss with no hx of thromboembolic disease?

2
2 Answers

Mednet MemberInvited Expert
Hematology · Oregon Health & Science University

First, it is essential to confirm that patients meet criteria for obstetric antiphospholipid antibody syndrome (OAPS), based on the 2023 ACR/EULAR classification criteria. This includes persistently positive laboratory criteria (confirmed on repeat testing >12 weeks apart), plus otherwise unexplaine...

Would you expect a reduced neutrophil count in individuals with a partial duffy null phenotype?

1 Answers

Mednet MemberInvited Expert
Hematology · Harvard Medical School

The Duffy null phenotype's impact on neutrophil counts is "all or none". Approximately one-third of patients with the Duffy null phenotype Fy (a-b-) will have a neutrophil count below the usual lower limit of normal. The range of neutrophil counts in individuals with Fy (a+b-) and Fy (a-b+) is exact...

In what clinical scenario would you consider liver transplant evaluation for a patient with sickle cell hepatopathy?

2 Answers

Mednet MemberInvited Expert
Hepatology · Johns Hopkins Medicine

We have evaluated and transplanted patients with sickle cell hepatopathy with severe liver dysfunction but well-controlled sickle cell. These patients will typically have jaundice, coagulopathy, and biliary strictures. They should not have significant extrahepatic complications of the hematologic di...

How do you decide whether to hold acalabrutinib or zanubrutinib in patients with indolent B-cell lymphoma/leukemias in a perioperative/periprocedural setting?

1 Answers

Mednet Member
Medical Oncology · University of Kansas Cancer Center

This is always a point of discomfort among providers, but it can actually be made quite easy. BTK inhibitors have known antiplatelet effects similar to low-dose aspirin. Consequently, if the surgeon holds aspirin for the planned procedure, I generally recommend that we hold the BTK inhibitor for 3 d...

What is your approach to VTE prophylaxis in hospitalized patients who are already on DAPT?

2
1 Answers

Mednet MemberInvited Expert
Hospital Medicine · University of California, San Francisco

DAPT by itself is not considered DVT prophylaxis in patients at high risk of DVT. However, LMWH at prophylactic doses can increase the need for transfusions in patients on DAPT, without decreasing VTE rates. In general, I consider patients individually: Do they still need DAPT? With discontinuity o...

Should all patients diagnosed with B12 deficiency get a baseline EGD?

1
1 Answers

Mednet MemberInvited Expert
Hematology · Rochester General Hospital

It is important to determine the cause of B12 deficiency. The majority of cases are due to pernicious anemia (atrophic gastritis and lack of intrinsic factor), I presume this question relates to that group. If there is another cause such as intestinal malabsorption or bacterial overgrowth, this does...

How will you use Pola-R-CHP in the frontline treatment of DLBCL?

4
3 Answers

Mednet MemberInvited Expert
Medical Oncology · Cleveland Clinic

Given the comparable toxicity profile and the lower rate of treatment failure, the number needed to treat (n=16) is low enough that this is very appropriate to be the new standard of care. Although overall survival was not different, fewer patients treated with the Pola-R-CHP regimen required subseq...